Hemodynamic effects of lipids in humans.
Evidence suggests lipid abnormalities may contribute to elevated blood pressure, increased vascular resistance, and reduced arterial compliance among insulin-resistant subjects. In a study of 11 normal volunteers undergoing 4-h-long infusions of Intralipid and heparin to raise plasma nonesterified fatty acids (NEFAs), we observed increases of blood pressure. In contrast, blood pressure did not change in these same volunteers during a 4-h infusion of saline and heparin. To better characterize the hemodynamic responses to Intralipid and heparin, another group of 21 individuals, including both lean and obese volunteers, was studied after 3 wk on a controlled diet with 180 mmol sodium/day. Two and four hours after starting the infusions, plasma NEFAs increased by 134 and 111% in those receiving Intralipid and heparin, P < 0.01, whereas plasma NEFAs did not change in the first group of normal volunteers who received saline and heparin. The hemodynamic changes in lean and obese subjects in the second study were similar, and the results were combined. The infusion of Intralipid and heparin induced a significant increase in systolic (13.5 +/- 2.1 mmHg) and diastolic (8.0 +/- 1.5 mmHg) blood pressure as well as heart rate (9.4 +/- 1.4 beats/min). Small and large artery compliance decreased, and systemic vascular resistance rose. These data raise the possibility that lipid abnormalities associated with insulin resistance contribute to the elevated blood pressure and heart rate as well as the reduced vascular compliance observed in subjects with the cardiovascular risk factor cluster.
Stojiljkovic
M P
MP
Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Zhang
D
D
Lopes
H F
HF
Lee
C G
CG
Goodfriend
T L
TL
Egan
B M
BM
D000328:Adult; D000925:Anticoagulants / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole; D004338:Drug Combinations; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007262:Infusions, Intravenous; D008055:Lipids / Q000494:pharmacology*; D008875:Middle Aged; D012965:Sodium Chloride / Q000494:pharmacology; D013599:Systole; D014655:Vascular Resistance / Q000187:drug effects; D014666:Vasomotor System / Q000187:drug effects
D000925:Anticoagulants; D004338:Drug Combinations; D005217:Fat Emulsions, Intravenous; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D012965:Sodium Chloride; D006493:Heparin